- Home
- ESPR vs III Comparison
ESPR vs III Comparison
Compare ESPR & III Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESPR
- III
- Stock Information
- Founded
- ESPR 2008
- III 2006
- Country
- ESPR United States
- III United States
- Employees
- ESPR N/A
- III N/A
- Industry
- ESPR Biotechnology: Pharmaceutical Preparations
- III Professional Services
- Sector
- ESPR Health Care
- III Consumer Discretionary
- Exchange
- ESPR Nasdaq
- III Nasdaq
- Market Cap
- ESPR 220.0M
- III 207.8M
- IPO Year
- ESPR 2013
- III 2007
- Fundamental
- Price
- ESPR $2.17
- III $5.03
- Analyst Decision
- ESPR Buy
- III Buy
- Analyst Count
- ESPR 6
- III 1
- Target Price
- ESPR $6.50
- III $5.50
- AVG Volume (30 Days)
- ESPR 5.2M
- III 280.8K
- Earning Date
- ESPR 08-05-2025
- III 08-06-2025
- Dividend Yield
- ESPR N/A
- III 3.58%
- EPS Growth
- ESPR N/A
- III N/A
- EPS
- ESPR N/A
- III 0.16
- Revenue
- ESPR $268,125,000.00
- III $240,201,000.00
- Revenue This Year
- ESPR $6.10
- III N/A
- Revenue Next Year
- ESPR N/A
- III $5.08
- P/E Ratio
- ESPR N/A
- III $32.05
- Revenue Growth
- ESPR N/A
- III N/A
- 52 Week Low
- ESPR $0.69
- III $2.95
- 52 Week High
- ESPR $3.94
- III $5.28
- Technical
- Relative Strength Index (RSI)
- ESPR 73.45
- III 62.80
- Support Level
- ESPR $2.00
- III $4.77
- Resistance Level
- ESPR $2.14
- III $5.04
- Average True Range (ATR)
- ESPR 0.15
- III 0.21
- MACD
- ESPR 0.02
- III 0.05
- Stochastic Oscillator
- ESPR 95.08
- III 91.96
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
About III Information Services Group Inc.
Information Services Group Inc is a U.S.-based technology insight, market intelligence, and advisory services firm. It principally offers digital transformation services, such as automation and cloud & data analytics; managed governance; network carrier services; technology plan and operations design; changes management; market intelligence & technology research and analysis. It operates in one segment, fact-based sourcing advisory services. Its geographical segments are the Americas, Europe, and Asia-pacific, out of which maximum revenue is derived from Americas.